The Zambia cholera vaccines market has been gaining prominence due to the increasing prevalence of cholera in the country. Cholera is an acute diarrheal infection caused by ingestion of food or water contaminated with the bacterium Vibrio cholera. The severity of the disease ranges from mild to severe cases. Oral cholera vaccines help induce protective immunity against cholera infection and prevent outbreaks. The oral vaccines Mimyc and Shanchol are commonly used in Zambia. Their advantages include easy administration through ingestion and induction of both secretory and systemic immunity. Cholera remains a major public health challenge in Zambia due to lack of access to clean water and sanitation.
Key Takeaways
Key players operating in the Zambia cholera vaccines market are Biovac Inc., Valneva SE., EMERGENT, Astellas Pharma Inc, Sanofi, EUBIOLOGICS CO., LTD,Johnson & Johnson Services Inc., Celldex Therapeutics.
Biovac Inc. and EPI-VASC have played a critical role in manufacturing and supply of oral cholera vaccines for Zambia. Valneva SE recently received prequalification from WHO for their oral cholera vaccine ‘Vaxchora’ paving way for expanded access.
The growing Zambia Cholera Vaccines Market Growth, initiatives toward disease prevention and outbreak control by WHO and global health organizations present lucrative growth opportunities. Increased funding and partnerships for mass vaccination campaigns will help achieve the goal of cholera elimination.
The major players are focused on expanding production and access of cholera vaccines in Africa. Partnerships with governments, aid agencies and local manufacturers will help step up supplies and distribution networks across endemic regions.
Market Drivers
The rising incidence of cholera cases in Zambia acts as a key driver for the market. According to WHO, there were more than 18,000 cases and 230 deaths reported between January to October 2020. The unsanitary conditions and limited access to clean water and toilets have increased the risk of infection.
Market Restraints
The major restraint is the requirement of extensive logistics and funding for mass immunization programs in remote regions and refugee camps which lack basic infrastructure. The high costs of vaccines also limit widespread adoption especially in resource-poor settings. Storage and distribution of oral vaccines within the cold chain presents operational challenges.
Segment Analysis
The Zambia cholera vaccines market is segmented into oral live attenuated cholera vaccine, oral live recombinant cholera vaccine, and inactivated oral cholera vaccines. The oral live attenuated cholera vaccine segment dominates the market owing to its effectiveness, affordability, and wide adoption. These vaccines provide longer-term protection and are suitable for mass vaccination campaigns in developing nations. Their ease of administration boosts their popularity.
Global Analysis
Regionally, Africa is the fastest growing as well as dominating regional market for Zambia cholera vaccines. This is majorly due to the high disease burden and ongoing vaccination programs. Countries like Zambia, Nigeria, and Democratic Republic of Congo contribute significantly to the regional market growth. Favourable governmental policies and initiatives for immunization programs further support market expansion. Developed regions also present remunerative opportunities due to better access to advanced vaccines and rising R&D investments of key players.
Get more insights on Zambia Cholera Vaccines Market
Comments
0 comment